Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Director Sells 5,000 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 5,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the transaction, the director now directly owns 16,641 shares of the company’s stock, valued at approximately $832,050. This represents a 23.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total transaction of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00.

Twist Bioscience Trading Down 3.4 %

Shares of TWST opened at $43.60 on Friday. The firm has a market cap of $2.59 billion, a P/E ratio of -12.11 and a beta of 1.85. The company’s 50-day moving average price is $46.40 and its 200 day moving average price is $46.41. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of research reports. Robert W. Baird raised their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. Barclays reduced their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Scotiabank upped their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Finally, TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter worth $34,000. Signaturefd LLC lifted its stake in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Twist Bioscience during the 2nd quarter worth about $61,000. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the 3rd quarter valued at about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.